证券日报网讯 8月22日晚间，金凯生科发布公告称，公司第二届董事会第八次会议审议通过了《关于调 整第二届董事会独立董事津贴的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The company announced that its second supervisory board meeting approved several proposals, including changing the implementation of certain fundraising projects from borrowing funds to increasing capital in subsidiaries using self-owned funds [2]

证券日报网讯金凯生科（301509）8月22日在互动平台回答投资者提问时表示，截至2025年8月20日，公 司股东数为14135户。 ...

格隆汇8月22日丨金凯生科(301509.SZ)公布，公司于2025年8月22日召开的第二届董事会第八次会议和第二届监事会第八次会议分别审议通过了《关于使用自有资金向子公司Kingchem Li ...

Core Viewpoint - Jinkai Biotechnology (301509.SZ) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue reached 348 million yuan, representing a year-on-year growth of 32.98% [1] - The net profit attributable to shareholders was 71.76 million yuan, showing a remarkable year-on-year increase of 123.61% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 59.17 million yuan, reflecting a year-on-year growth of 141.51% [1] - Basic earnings per share stood at 0.6 yuan [1]

Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance [1] Financial Performance - The company achieved an operating income of 348 million yuan, representing a year-on-year growth of 32.98% [1] - The net profit attributable to shareholders reached 71.76 million yuan, showing a remarkable year-on-year increase of 123.61% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 59.17 million yuan, reflecting a year-on-year growth of 141.51% [1] - The basic earnings per share stood at 0.60 yuan [1]

Core Viewpoint - Kingchem Life Science LLC, a subsidiary of Jinkai Life Science Co., Ltd., is set to receive a capital increase of $32 million for the expansion of Kingchem Laboratories Inc. [2] Group 1: Company Announcement - On August 22, 2025, the second board meeting and the second supervisory board meeting of Jinkai Life Science Co., Ltd. approved the proposal for using self-owned funds to increase capital for its subsidiary [2] - The board has authorized the management to handle the overseas investment procedures related to this capital increase, with the authorization period starting from the board's approval until the completion of the investment procedures [2]

金凯（辽宁）生命科技股份有限公司 关于使用自有资金向子公司Kingchem Life Science LLC增资 用于Kingchem Laboratories Inc.实施建设的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、投资概述 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于2025年8月22日召 开的第二届董事会第八次会议和第二届监事会第八次会议分别审议通过了《关于使 用自有资金向子公司Kingchem Life Science LLC增资用于Kingchem Laboratories Inc.实施建设的议案》，同意公司投资3,200万美元用于Kingchem Laboratories Inc.（以下简称"KLI"）扩建项目（以下简称"本次投资"）。董事会授权公司管 理层办理本次增资的境外投资手续，授权期限自董事会审议通过之日起至本次增资 的境外投资手续办理完毕之日止。 证券代码：301509 证券简称：金凯生科 公告编号：2025-029 本次投资事宜在董事会审批权限范围内，无须提交公司股东会审议。本次投资 事项不构成关联交易，亦 ...

（文章来源：每日经济新闻） 金凯生科8月22日晚间发布半年度业绩报告称，2025年上半年营业收入约3.48亿元，同比增加32.98%； 归属于上市公司股东的净利润约7176万元，同比增加123.61%；基本每股收益0.6元，同比增加 122.22%。 ...

（文章来源：每日经济新闻） 金凯生科8月22日晚间发布公告称，公司第二届第八次董事会会议于2025年8月22日在公司会议室以现场 会议结合通讯方式召开。会议审议了《关于<2025年半年度报告>及其摘要的议案》等文件。 ...